study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Summary: this is a phase 3, open-label study to evaluate the objective response rate (orr), in patients with metastatic pancreatic ductal adenocarcinoma (mpdac) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.

relacorilant is a small-molecule antagonist of the glucocorticoid receptor (gr). the goals of this study are to evaluate the efficacy, safety, and pharmacokinetics (pk) of relacorilant in combination with nab-paclitaxel in the treatment of metastatic pancreatic ductal adenocarcinoma. eligible patients are those with mpdac who have received at least 2 prior lines of therapy for pancreatic ductal adenocarcinoma in any setting, including at least 1 prior gemcitabine-based therapy and at least 1 prior fluoropyrimidine-based therapy. patients will receive treatment until progressive disease (pd) (per recist v1.1) as determined by the investigator, experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. all patients will be followed for documentation of disease progression and survival information (i.e., date and cause of death) and subsequent treatment.

Eligibility criteria:
inclusion criteria - patients must have the following: histologically confirmed pdac with metastatic disease received at least 2 prior lines of therapy for pdac in any setting, including at least 1 prior gemcitabine-based therapy and at least 1 prior fluoropyrimidine-based therapy received no more than 4 prior lines of cytotoxic or myelosuppressive therapy for pdac a measurable lesion at baseline (within 21 days prior to the first dose of relacorilant) per recist v1.1, as assessed by the investigator willingness to provide blood samples and tumor tissue (primary or metastatic) for research purposes karnofsky performance status (kps) score of ≥70 adequate gastrointestinal absorption. if the patient has undergone gastric bypass surgery and/or surgery of gastrointestinal or hepatobiliary tract, the patient must demonstrate adequate absorption as evidenced by albumin ≥3.0 g/dl, controlled pancreatic insufficiency (if present), and lack of evidence of malabsorption adequate organ and marrow function (determined through blood and urine tests) exclusion criteria - patients must not have the following: pancreatic neuroendocrine tumors, lymphoma of the pancreas, acinar pancreatic cancer, or ampullary cancer known untreated parenchymal brain metastasis or have uncontrolled central nervous system metastases. patients must not require steroids and must be neurologically stable without corticosteroids for a minimum of 3 weeks prior to cycle 1 day 1 clinically relevant toxicity from prior systemic cytotoxic therapies or radiotherapy that in the opinion of the investigator has not resolved to grade 1 or less prior to enrollment, including peripheral neuropathy that is ongoing and greater than grade 1 in severity, according to national cancer institute common terminology criteria for adverse events (nci-ctcae) v5.0 history of hypersensitivity or severe reaction to either relacorilant or nab-paclitaxel, or to similar classes of either drug taken the following medications prior to enrollment: 1. an investigational product, cytotoxic chemotherapy, or targeted agent within 14 days 2. radiotherapy within 21 days 3. palliative radiotherapy within 1 week of cycle 1 day 1, or if toxicities from radiotherapy are grade 2 severity or higher or have not recovered to baseline 4. systemic or prescription-strength topical corticosteroids for the purposes of treating a chronic nononcologic indication within 21 days. requirement for treatment with chronic or frequently used oral or inhaled corticosteroids for medical conditions or illnesses (e.g., rheumatoid arthritis, asthma, or immunosuppression after organ transplantation) taking a concomitant medication that is a strong cyp3a (cytochrome p450 3a) or cyp2c8 inhibitor or inducer, or a substrate of cyp3a or cyp2c8 and has a narrow therapeutic window concurrent treatment with mifepristone or other gr antagonists any clinically significant uncontrolled condition(s) or any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities or impair study participation or cooperation any major surgery within 21 days prior to enrollment endoscopic retrograde cholangiopancreatography with persistence of any of the following: 1. bilirubin ≥1.5 × uln (upper limit of normal) 2. amylase \>2 × uln and abdominal pain or amylase \>3 × uln (with or without symptoms) 3. fever or signs of infection 4. decreasing hemoglobin or signs of blood loss. a history of human immunodeficiency virus (hiv) or current chronic/active infection with hepatitis c virus (hcv) or hepatitis b virus (hbv). (patients with chronic or active hepatitis b as diagnosed by serologic tests are excluded from the study. in equivocal cases, hepatitis b or c polymerase chain reaction results may be performed and must be negative for enrollment.) a rapid decline in kps score or serum albumin (≥20%), or have progressive pain symptoms indicative of rapid clinical deterioration, in the opinion of the investigator, prior to enrollment. these patients will become ineligible if rapid decline is observed during the screening period.

Keywords: pancreatic cancer mpdac metastatic pancreatic ductal adenocarcinoma glucocorticoid receptor nab-paclitaxel gr antagonist relacorilant abraxane